Literature DB >> 21924580

Impact of female sex on long-term outcomes in patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention.

Giuseppe Ferrante1, Elena Corrada, Guido Belli, Dennis Zavalloni, Melania Scatturin, Marco Mennuni, Gabriele L Gasparini, Luisa Bernardinelli, Daniela Cianci, Roberta Pastorino, Marco L Rossi, Paolo Pagnotta, Patrizia Presbitero.   

Abstract

BACKGROUND: Conflicting information exists about whether sex differences affect long-term outcomes in patients undergoing primary percutaneous coronary intervention (PCI).
METHODS: This retrospective study enrolled consecutive patients with ST-elevation myocardial infarction undergoing primary PCI within 24 hours from symptom onset. Hazard ratios (HRs) of events with 95% confidence interval (CI) were calculated in the overall population and in a propensity score matched cohort of women and men.
RESULTS: Among 481 patients, median age 66 years old, 138 (28.7%) were women. Women were older than men (72 vs 63 years, P<0.001), had a higher prevalence of hypertension (68% vs 54%, P=0.006), diabetes (27% vs 19%, P=0.04), and Killip class≥3 at admission (19% vs 10%, P=0.007). After a median follow-up of 1041 days women experienced a significant higher incidence of the composite of death, nonfatal myocardial infarction, and hospitalization for heart failure (31.9% vs 18.4%, unadjusted HR 1.86; 95% CI, 1.26-2.74; P=0.002), driven mainly by heart failure (unadjusted HR 2.47; 95% CI, 1.12-5.41; P=0.024), without significant differences in death (unadjusted HR 1.49; 95% CI, 0.88-2.53; P=0.13), or nonfatal myocardial infarction (unadjusted HR 1.59; 95% CI, 0.78-3.27; P=0.19) and no increase in target lesion revascularization (9.4% vs 12.5%, unadjusted HR 0.77; 95% CI, 0.42-1.44; P=0.42). After propensity score matching the hazard of the composite endpoint was largely attenuated (HR 1.32; 95% CI, 0.84-2.06; P=0.23).
CONCLUSIONS: Women undergoing primary PCI experience worse long-term outcomes than men, but this difference is largely explained by their more adverse baseline cardiovascular profile.
Copyright © 2011 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21924580     DOI: 10.1016/j.cjca.2011.07.002

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  6 in total

Review 1.  Gender Disparities in Presentation, Management, and Outcomes of Acute Myocardial Infarction.

Authors:  Matthew Liakos; Puja B Parikh
Journal:  Curr Cardiol Rep       Date:  2018-06-16       Impact factor: 2.931

2.  Interleukin 17A in Patients With Stable Coronary Artery Disease: Are There Differences According to Gender?

Authors:  Dinaldo Oliveira; Elayne Heide; Carlos Brandt; Moacyr Rego; Maira Pitta; Ivan Pitta
Journal:  Cardiol Res       Date:  2014-12-04

Review 3.  Outcomes After Percutaneous Coronary Intervention in Women: Are There Differences When Compared with Men?

Authors:  Usha Rao; G Louise Buchanan; Angela Hoye
Journal:  Interv Cardiol       Date:  2019-05-21

4.  Evaluation of sex differences in patients with ST-elevated myocardial infarction: an observational cohort study in Amsterdam and surrounding region.

Authors:  T Kerkman; L B G Ten Brinke; B Huybrechts; R Adams; G Amoroso; R J de Winter; Y Appelman
Journal:  Neth Heart J       Date:  2020-11       Impact factor: 2.380

5.  Sex-specific outcomes of diabetic patients with acute myocardial infarction who have undergone percutaneous coronary intervention: a register linkage study.

Authors:  Mai Blöndal; Tiia Ainla; Toomas Marandi; Aleksei Baburin; Jaan Eha
Journal:  Cardiovasc Diabetol       Date:  2012-08-11       Impact factor: 9.951

Review 6.  Gender difference in clinical outcomes of the patients with coronary artery disease after percutaneous coronary intervention: A systematic review and meta-analysis.

Authors:  Yaya Guo; Fahui Yin; Chunlei Fan; Zhilu Wang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.